AUTHORS
Nitin Jain, MD, Alessandra Ferrajoli III, MD2, Mahesh Swaminathan, MD3, Jan A. Burger, MD, PhD4, Hannah Goulart, MD5, Wei Ying Jen, BM BCh, FRCPath6, Hima Atluri, MD7, Alex Bataller, MD, PhD8, Elias Jabbour, MD9, Tapan Kadia I, MD10, Gautam Borthakur, MD11, Naveen Pemmaraju, MD12, Koichi Takahashi, MD,PhD13, Lucia Masarova, MD14, Kelly Sharon Chien, MD15, Musa Yilmaz, MD16, Naval Daver, MD17, Fadi G. Haddad, MD18, Yesid Alvarado Valero, MD19, Jo Ishizawa, MD, PhD20, Guillermo Montalban-Bravo, MD21, Naveen Garg22, Hyunsoo Hwang23, Wei Qiao24, Cameron Garcia25, Anna Evangelio26, Bridget Marchant27, Ana Ayala28, Deepa Sampath, PhD29, Varsha Gandhi, PhD30, Guillermo Garcia-Manero, MD31, Hagop Kantarjian, MD32, William G. Wierda, MD, PhD33
AFFILIATIONS
1 MD Anderson Cancer Center, Houston, Texas, United States
2 MD Anderson Cancer Center, Houston, Texas, United States
3 MD Anderson Cancer Center, Houston, Texas, United States
4 MD Anderson Cancer Center, Houston, Texas, United States
5 MD Anderson Cancer Center, Houston, Texas, United States
6 MD Anderson Cancer Center, Houston, Texas, United States
7 MD Anderson Cancer Center, Houston, Texas, United States
8 MD Anderson Cancer Center, Houston, Texas, United States
9 MD Anderson Cancer Center, Houston, Texas, United States
10 MD Anderson Cancer Center, Houston, Texas, United States
11 MD Anderson Cancer Center, Houston, Texas, United States
12 MD Anderson Cancer Center, Houston, Texas, United States
13 MD Anderson Cancer Center, Houston, Texas, United States
14 MD Anderson Cancer Center, Houston, Texas, United States
15 MD Anderson Cancer Center, Houston, Texas, United States
16 MD Anderson Cancer Center, Houston, Texas, United States
17 MD Anderson Cancer Center, Houston, Texas, United States
18 MD Anderson Cancer Center, Houston, Texas, United States
19 MD Anderson Cancer Center, Houston, Texas, United States
20 MD Anderson Cancer Center, Houston, Texas, United States
21 MD Anderson Cancer Center, Houston, Texas, United States
22 MD Anderson Cancer Center, Houston, Texas, United States
23 MD Anderson Cancer Center, Houston, Texas, United States
24 MD Anderson Cancer Center, Houston, Texas, United States
25 MD Anderson Cancer Center, Houston, Texas, United States
26 MD Anderson Cancer Center, Houston, Texas, United States
27 MD Anderson Cancer Center, Houston, Texas, United States
28 MD Anderson Cancer Center, Houston, Texas, United States
29 MD Anderson Cancer Center, Houston, Texas, United States
30 MD Anderson Cancer Center, Houston, Texas, United States
31 MD Anderson Cancer Center, Houston, Texas, United States
32 MD Anderson Cancer Center, Houston, Texas, United States
33 MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background: Use of targeted therapies such as covalent (c)BTK inhibitors (BTKi), BCL2 inhibitors (BCL2i), and CD20 monoclonal antibody are approved for first-line treatment of patients with chronic lymphocytic leukemia (CLL). Pirtobrutinib, a non-covalent (nc)BTKi is approved for relapsed CLL. Prior studies have shown high rates of undetectable measurable residual disease (U-MRD) remission in patients who receive combined treatment with cBTKi and BCL2i with or without obinutuzumab.
Methods: We conducted an investigator-initiated phase 2 trial of combined pirtobrutinib, venetoclax, and obinutuzumab in treatment-naïve patients with CLL who met iwCLL treatment criteria. Patients received pirtobrutinib 200mg once daily and obinutuzumab starting cycle 1. Venetoclax standard ramp-up was initiated in cycle 2 to the target dose of 400mg daily. Obinutuzumab (standard dosing) was given for 6 cycles and pirtobrutinib and venetoclax were continued until cycle 13. Response evaluations (2018 iwCLL criteria) were done by imaging and bone marrow (BM) assessment at end of cycles 7 and 13. MRD was assessed by next-generation sequencing in both blood and BM. Patients with detectable MRD5 (≥10-5) at the end of cycle 13 could continue pirtobrutinib and venetoclax for another 12 cycles. The primary endpoint was rate of BM U-MRD4 (10-4 sensitivity) after cycle 7.
Results: Between February 2023 and September 2024, 80 pts were enrolled. Median age was 63 years; 79% had IGHV-unmutated CLL; and 13% had del(17p) and/or TP53 mutation.
3 pts came off trial (1 pt in C3 for treatment of newly diagnosed head/neck cancer; 2 pts in C1 due to travel logistics and insurance denial); the remaining 77 pts continued on trial. The median follow-up for all pts is 29.8 months.
After cycle 7, BM U-MRD4 (primary endpoint) remission was achieved in 88% of the pts. After cycle 7 and cycle 13, the BM U-MRD6 (10-6 sensitivity) remission rates were 61% and 74%, respectively; the corresponding rates for blood were 75% and 86%, respectively. No pt had CLL progression. One pt died from infectious complications after completing therapy. 2-year PFS and OS were both 98.7%.
Among the 66 pts who finished treatment per protocol at the end of cycle 13, at a median follow-up of 17.9 months (range, 7.8-26.6 months) post treatment discontinuation, 1 pt had MRD4 recurrence (defined as MRD ≥0.01% in blood on 2 consecutive tests). Grade 3-4 neutropenia and thrombocytopenia occurred in 67% and 19% pts, respectively.
Conclusions: Combined pirtobrutinib, venetoclax, and obinutuzumab leads to high BM U-MRD6 remission rate in pts with previously untreated CLL. An additional cohort of 80 treatment-naïve pts with CLL is enrolling and updated data for all 160 pts will be presented.
DISCLOSURES
Nitin Jain, MD: BMS - Honoraria; Kite/Gilead - Honoraria; Pharmacyclics - Honoraria; Adaptive Biotechnologies - Honoraria; SERB Pharma - Honoraria; Autolus - Honoraria; AstraZeneca - Honoraria; BeOne - Honoraria; Cellectis - Honoraria; Nurix - Honoraria; Genentech - Honoraria; Eli Lilly - Honoraria; AbbVie - Honoraria; Janssen - Honoraria; BeOne - Research Funding; AstraZeneca - Research Funding; Kite/Gilead - Research Funding; Adaptive Biotechnologies - Research Funding; Cellectis - Research Funding; Newave - Research Funding; Ubix Therapeutics - Research Funding; Takeda - Research Funding; ADC Therapeutics - Research Funding; Carna Biosciences - Research Funding; Genentech - Research Funding; Ascentage - Research Funding; Eli Lilly - Research Funding; Bioheng Therapeutics - Research Funding; AbbVie - Research Funding; BMS - Research Funding; Pharmacyclics - Research Funding; AbbVie - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); Cellectis - Consultancy (Includes expert testimony); SERB Pharma - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); Autolus - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Pharmacyclics - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Nurix - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Adaptive Biotechnologies - Consultancy (Includes expert testimony); Kite/Gilead - Consultancy (Includes expert testimony)